What happens when a therapy depends on both a pharmaceutical compound and a medical device working together as a single system?
In many modern treatments, that integration is exactly what makes the therapy possible. Drug-device combination products bring pharmaceutical compounds and medical devices together to deliver medication in controlled, targeted ways. Common examples include auto-injectors, inhalers, infusion systems, and implantable platforms that release medication over time.
This integration introduces additional complexity during development. Drug stability, device functionality, and sterility protection must all remain intact from manufacturing through distribution and clinical use. Packaging, therefore, becomes a central part of the product system. It protects multiple regulated components, supports safe handling in clinical environments, and aligns with both pharmaceutical and device regulatory frameworks.
For manufacturers preparing packaging for combination products, these demands translate into a broader set of packaging responsibilities. The system must maintain sterile barrier integrity, preserve drug compatibility, shield device components from mechanical stress, and support the documentation required throughout the product lifecycle.
Because of this expanded role, drug-device combination product packaging must be designed with regulatory expectations, risk management strategies, validation requirements, and long-term lifecycle oversight in mind. This guide explores the key considerations involved in building packaging systems that support those objectives.
Understanding Drug-Device Combination Products
A drug-device combination product contains two or more regulated parts that work together as a single therapeutic system. These systems may include a drug combined with a device, a biological product integrated into a delivery mechanism, or multiple components assembled in a single treatment kit.
The global market for these products is expanding rapidly, valued at approximately $224.7 billion in 2024 and projected to grow at a compound annual growth rate (CAGR) of nearly 9.3% through 2030.
When it comes to regulators, they categorize combination products based on the primary mode of action, meaning the component that produces the main therapeutic effect. This designation determines which FDA center takes primary responsibility for the premarket review.
Examples include:
- A prefilled drug delivery device, such as an autoinjector
- Surgical kits containing co-packaged drugs with sterile instruments
- Implantable pumps delivering active pharmaceutical ingredients
- Inhalation systems integrating pharmaceutical and device components.
These products may include components classified differently under device rules. A delivery system might be a Class II device, while certain accessories may fall under Class I device classifications.
In the U.S., the FDA’s 21 CFR Part 4 provides the specific framework for these “cross-labeled” or co-packaged products, ensuring they meet the Current Good Manufacturing Practice (CGMP) requirements for both drugs and devices. Packaging, therefore, becomes part of the broader regulatory strategy because it must protect every component and support the product’s safe use.
Regulatory Framework Governing Combination Product Packaging
Drug-device combination products must comply with both pharmaceutical and device regulations. In the United States, oversight is coordinated through the FDA Office of Combination Products, while the responsible FDA center depends on the product’s primary mode.
Manufacturers must address multiple regulatory layers:
Device and Drug Regulatory Requirements
Packaging decisions must align with requirements under device and drug regulations such as:
- Medical Devices Regulations
- The Food and Drugs Act
- Global rules governing Natural health products
- Regulatory pathways for Advanced Therapeutic Products.
Products under development often begin under an investigational application, accompanied by an investigational plan outlining safety studies, packaging validation strategy, and stability testing.
Later, data from these studies supports the marketing application submitted during regulatory review.
Standards and Quality Systems
Combination product manufacturers often rely on recognized consensus standards and guidelines developed by the International Organization for Standardization (ISO) to support compliance. ISO 11607 remains the gold standard for terminal sterilization packaging, a critical benchmark considering that even a microscopic breach in a sterile barrier can lead to a 100% loss of product integrity.
At the facility level, packaging operations must follow Good Manufacturing Practices. These standards govern environmental controls, documentation procedures, and traceability for every component entering the packaging line.
Packaging Challenges Unique to Combination Products
Traditional pharmaceutical packaging and standard device packaging follow different design logic. Combination products bring these two systems together, which introduces several technical challenges.
Protecting Multiple Regulated Components
A combination product package may contain:
- A drug container closure system
- A device component or delivery mechanism
- Accessories and instructions for use.
Each device constituent must remain protected from mechanical damage, contamination, and environmental exposure. Packaging also needs to maintain the stability of Active Pharmaceutical Ingredients (APIs) over time. For biologics, which represent a significant portion of new combination products, maintaining a cold chain is vital; the World Health Organization (WHO) estimates that up to 50% of vaccines are wasted each year globally, often due to temperature excursions during transport and storage.
Sterility and Stability Considerations
Many combination products are sterile systems. The packaging configuration must support validated sterilization methods and maintain sterile barrier integrity until clinical use.
Drug stability studies also play a role. The package must maintain temperature and moisture conditions that preserve the therapeutic compound throughout distribution and storage.
Risk Management in Combination Product Packaging
Because combination products integrate drug and device technologies, packaging design becomes a central element of product safety. Manufacturers typically create structured Risk Management Plans early in development, often following the ISO 14971 standard for the application of risk management to medical devices. These plans identify hazards associated with transport, storage, handling, and clinical use.
Examples of packaging-related risks include:
- Device misalignment during shipping
- Sterile barrier damage during distribution
- Confusion between components in multi-item kits.
To address these risks, teams implement documented risk mitigation measures, such as protective trays, immobilization features, and validated sealing methods.
Risk management continues beyond product launch. Safety reporting obligations require manufacturers to monitor field performance and investigate packaging-related incidents.
Design Verification and Packaging Validation
Before commercialization, packaging must pass formal testing to confirm it performs as intended.
This phase typically includes:
- Design verification testing for packaging strength and durability
- Transport simulation and vibration testing
- Seal integrity testing for sterile barrier systems
- Environmental conditioning and stability testing.
These evaluations demonstrate that packaging meets applicable Essential Performance Requirements and protects the product throughout distribution.
Validation documentation becomes part of the regulatory submission package during premarket review.
Lifecycle Management and Postmarket Responsibilities
Packaging development does not end once the product reaches the market. Manufacturers maintain oversight through structured Lifecycle Management processes.
Regulatory frameworks require ongoing monitoring, including:
- complaint investigations
- field performance reviews
- updates required by postmarket regulation.
Packaging modifications may occur over time to improve operational efficiencies, address supply chain changes, or incorporate updated regulatory guidance.
Every change must be evaluated carefully, as packaging adjustments can influence sterility validation, product stability, and regulatory status.
The Role of Specialized Contract Manufacturers
Developing packaging for combination products requires coordination between pharmaceutical scientists, device engineers, packaging specialists, and regulatory teams. Packaging decisions often intersect with drug stability studies, device protection requirements, sterilization validation, and documentation needed for regulatory submissions.
Contract manufacturing organizations frequently support this process by providing:
- sterile barrier system design
- combination product assembly and kitting
- packaging validation and testing
- regulatory documentation support.
Working with partners experienced in both drug and device requirements helps reduce development delays and improves alignment across regulatory expectations. Facilities that operate under ISO 13485 quality systems and follow pharmaceutical Good Manufacturing Practices can help manufacturers manage the complexity associated with integrated drug-device systems.
Organizations such as PRO-TECH Design support these programs by providing contract packaging, assembly, and sterilization services for medical devices and combination products. With ISO 13485–certified operations and a drug-licensed facility in Minnesota, our team of experts can package drug-device combination products alongside device assemblies, allowing manufacturers to coordinate packaging workflows for products that contain both pharmaceutical and device components.
Conclusion
As combination therapies continue to evolve, packaging increasingly becomes part of the therapeutic system itself. Decisions made during packaging development influence regulatory readiness, manufacturing scalability, and how reliably a therapy can be delivered in clinical environments. Small changes in packaging configuration can affect sterility validation, drug stability studies, device protection, and user interaction during treatment preparation.
For manufacturers developing drug-device combination products, this means the packaging strategy should be considered early in product development rather than addressed late in the process. Early coordination between engineering, regulatory, and packaging teams helps reduce redesign cycles and supports a smoother path toward regulatory submission and commercialization.
This is where experienced manufacturing partners can add meaningful value. PRO-TECH Design supports combination product programs with ISO 13485-certified packaging, assembly, and sterilization services.
If your team is preparing a combination product for clinical trials or commercial production, reach out to PRO-TECH Design to discuss your packaging and manufacturing requirements.
FAQs
What is drug-device combination product packaging?
Drug-Device Combination Product Packaging refers to packaging systems designed to contain and protect integrated therapeutic products that combine pharmaceuticals with medical devices.
The package must safeguard both the drug formulation and the device component while meeting regulatory expectations from pharmaceutical and device authorities.
What are common examples of packaging for combination products?
Examples include packaging systems for autoinjectors and Prefilled Drug Delivery Device systems, surgical kits containing co-packaged drugs, inhalation therapy systems, and implantable drug delivery pumps.
These products often include multiple regulated components within a single packaging configuration.
How is the regulatory authority determined for combination products?
Regulatory responsibility depends on the primary mode of action. This determines which FDA center leads the premarket review process.
The designation identifies whether the therapeutic effect comes primarily from the drug, device, or biological product component.
What standards apply to packaging for combination products?
Manufacturers frequently reference consensus standards developed by the International Organization for Standardization and follow quality requirements defined under Good Manufacturing Practices.
Additional regulatory expectations may come from device or pharmaceutical regulations, depending on the product classification.
Why is risk management important in combination product packaging?
Combination products involve interacting technologies. Packaging, therefore, becomes part of the safety system.
Structured Risk Management Plans identify potential hazards during shipping, storage, and use. Teams then implement documented risk mitigation measures to reduce those risks before commercialization.
How does packaging support regulatory submissions?
Packaging validation data is required for regulatory submissions. Testing, such as Design Verification, seal integrity studies, and transport simulation, demonstrates compliance with Essential Performance Requirements and supports the product’s marketing application.
What role does packaging play after product launch?
After commercialization, manufacturers continue monitoring packaging performance through safety reporting, complaint investigations, and postmarket regulation requirements.
These activities feed into long-term Lifecycle Management, helping manufacturers maintain product reliability and regulatory compliance.